Testimony on SB 1525 (No Prior Authorization for Chronic Medications) 4.23.25
TAHP opposes Senate Bill 1525, which would broadly eliminate prior authorization (PA) requirements for chronic prescription drugs. The bill’s definition of “chronic” is so expansive that it would prevent PAs for medications with serious safety concerns—including opioids, antipsychotics, and drugs with FDA black box warnings. PAs protect patients from dangerous drug interactions, overuse, and misprescribing—especially for high-risk medications like Alzheimer’s treatments or antipsychotics in children. Texas already has strong PA safeguards, including goldcarding and strict timelines. SB 1525 would bypass these protections and increase the risk of preventable harm, fraud, and waste.
Click here to view TAHP’s testimony in response to SB 1525.
